By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
The European Stroke Organization And Boehringer Ingelheim Launch The "Angels Initiative", A Unique Healthcare Initiative To Improve Acute Stroke Care Across Europe 7/20/2016 11:26:58 AM
Boehringer Ingelheim And University of Dundee Collaborate To Develop New Class Of Medicines 7/14/2016 10:25:36 AM
Boehringer Ingelheim And Eli Lilly (LLY) Announce Clinical Trial Collaboration In Metastatic Breast Cancer 7/13/2016 10:29:28 AM
Boehringer Ingelheim Release: INMARK Now Enrolling: First Study To Evaluate The Effect Of OFEV (Nintedanib) On Biomarkers Reflecting The Underlying Fibrotic Process In IPF Patients 6/30/2016 9:03:29 AM
Only Days After Inking Asset Swap Deal With Sanofi (SNY), Boehringer Ingelheim Cuts 725 Jobs in the U.S. 6/30/2016 6:55:11 AM
FDA Panel Narrowly Backs Cardiovascular Claims for Boehringer Ingelheim, Eli Lilly (LLY)'s Jardiance 6/29/2016 6:11:04 AM
Sanofi (SNY) Inks Deal to Swap Business with Boehringer Ingelheim 6/27/2016 6:16:17 AM
Boehringer Ingelheim And Eli Lilly (LLY) Release: Jardiance (Empagliflozin) Significantly Reduced The Risk Of Progressive Kidney Disease In Adults With Type 2 Diabetes With Established Cardiovascular Disease 6/14/2016 10:36:23 AM
Boehringer Ingelheim And Eli Lilly (LLY) Release: New Study Results Show Trajenta (Linagliptin) Reduces Blood Sugar In Adults With Type 2 Diabetes At Risk For Kidney Impairment 6/13/2016 10:53:16 AM
Boehringer Ingelheim And HealthPrize Partner To Launch New Support Program For People Treating COPD With SPIRIVA RESPIMAT (Tiotropium Bromide) Inhalation Spray 6/8/2016 10:32:54 AM